2026. Computational Analysis of FDA-Approved Drugs for Potential Repurposing in Alzheimer’s Disease: Targeting mTOR and NGFR Pathways. Science Essence Journal. 42, 1 (Jan. 2026), 50–70. DOI:https://doi.org/10.69523/sej.2026.42.17130.